10-K: Global Innovative Platforms Advances Animal Health Diagnostics

Global Innovative Platforms Inc. reports significant R&D progress in breath analysis for animal disease detection, despite ongoing losses and a going concern warning.

Summary

• Global Innovative Platforms Inc. (GIPL) is focused on advancing animal health through non-invasive breath analysis and air quality technology, utilizing proprietary VOCAM Plus and FROG devices with A.I. software.
• The company's initial priority is developing a breath test for early-stage and mature heartworm infections in dogs, aiming to outperform traditional blood-based antigen tests which require the heartworm to be approximately six months old.
• GIPL is in the Algorithm Development stage for its Heartworm Breath Test, having gathered samples from 60 dogs (23 heartworm positive) and identified a pattern of VOCs believed to indicate heartworm presence without false positives in an initial 8-dog study.
• Following development of breath signature markers, the company compared 35 samples against its model, achieving 100% accuracy in research laboratory settings.
• The company plans verification and validation studies for the Heartworm Breath Test components in 2026, anticipating commercialization, though there is no guarantee of meeting milestones or market acceptance.
• GIPL has licensed exclusive global rights to certain patents and know-how from Defiant Technologies Inc. for animal testing and commercial applications, paying $150,000 to date and owing a 3% royalty on net sales.
• The company reported a net loss of $718,251 for the fiscal year ended September 30, 2025, compared to $136,197 in 2024, with an accumulated deficit of $1,255,464.
• No revenue was recognized for the years ended September 30, 2025, and 2024, but $85,000 was billed and collected subsequent to September 30, 2025.
• The company's independent public accountants issued an explanatory paragraph stating substantial doubt about its ability to continue as a going concern due to recurring losses and dependence on additional financing.
• Subsequent to the fiscal year end, GIPL announced an agreement with Boehringer Ingelheim Animal Health USA Inc. for evaluation and validation of its VOCAM Plus diagnostic technology for heartworm disease in dogs.

Sentiment

Score: 3

Explanation: The company shows promising early-stage research results and a significant partnership, but these are overshadowed by substantial financial losses, a going concern warning, no revenue, and significant internal control deficiencies. The business is highly speculative and dependent on future capital raises.

Positives

• Achieved 100% accuracy in research laboratory settings when comparing 35 samples against its heartworm breath test model, following initial identification of breath signatures for mature and early-stage heartworm.
• Entered into an agreement with Boehringer Ingelheim Animal Health USA Inc. for evaluation and validation of the VOCAM Plus diagnostic technology, marking a milestone in commercialization strategy.
• Proprietary technologies (VOCAM Plus and FROG) utilize advanced gas chromatography and A.I. software for rapid and accurate breath and air analysis, with the VOCAM Plus unit sophisticated enough to read Parts Per Trillion.
• The Heartworm Breath Test aims for earlier detection than current antigen tests (which require heartworms to be ~6 months old), is non-invasive, and can monitor treatment response.
• The A.I. software, Ellvin, is cloud-based and designed to constantly learn and improve testing performance as data accumulates, with potential for multi-disease testing from a single sample.
• The company believes its direct and amortized costs per use for the breath test will be less than a dollar, offering a more cost-effective alternative to current market leaders (approximately $5 per test).

Negatives

• Incurred a net loss of $718,251 for the fiscal year ended September 30, 2025, significantly higher than the $136,197 loss in 2024.
• Reported an accumulated deficit of $1,255,464 as of September 30, 2025.
• No revenue was recognized for the fiscal years ended September 30, 2025, and 2024, indicating the company is still in the pre-commercialization stage.
• The independent registered public accountants issued a going concern explanatory paragraph, citing substantial doubt about the company's ability to continue operations.
• The company has limited operating history and an evolving business model, raising doubt about its ability to achieve profitability or obtain future financing.
• Internal control over financial reporting was deemed ineffective as of September 30, 2024, due to inadequate segregation of duties, lack of accounting expertise, and insufficient oversight.
• The company is dependent on raising additional debt or equity financing to meet ongoing operating expenses and fund its business plan, with no committed source of funds.
• Some patents underlying the licensed technology from Defiant Technologies Inc. have expired, potentially allowing competitors to develop similar technologies without infringement.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and dependence on external financing.
• Limited operating history and an evolving business model, making it difficult to assure profitability or future financing.
• The speculative nature of the business plan may result in the loss of investors' entire investment if the company is unsuccessful in implementing its plan or if demand for services is lower than anticipated.
• Potential delays in implementing the business plan due to lack of capital, issues with product testing, or inability to hire and train additional personnel.
• General economic factors may negatively impact the market for veterinary products, as pet owners and the agricultural industry may consider these discretionary expenses.
• Reliance on the License Agreement with Defiant Technologies Inc. for VOCAM Plus technology; termination, non-renewal, or inability to secure continued access could halt development.
• Risks related to expired patents on licensed technology, potentially leading to increased competition and reduced market share.
• The stock is thinly traded, which may make it difficult for investors to sell shares at or near ask prices, or at all.
• As an issuer of penny stock, the company does not benefit from the federal securities law's safe harbor for forward-looking statements, increasing legal risk.
• Deficiencies in internal controls over financial reporting, including inadequate segregation of duties and lack of accounting expertise, increase the likelihood of undiscovered errors.
• The company's sole director does not have formal cybersecurity oversight, and IT staff lack specialized training, potentially exposing the company to material cybersecurity risks.
• Potential for significant dilution to existing stockholders if additional capital is raised through equity or equity-linked securities.
• The company does not intend to pay dividends, so investor returns depend solely on stock price appreciation, which is subject to high volatility.

Future Outlook

The company anticipates completing verification and validation studies for the Heartworm Breath Test components in 2026, aiming for commercialization. It expects research, product launch, and development expenses to increase as it completes modifications and pursues future product candidates. The company intends to continue developing non-invasive breath tests for up to nine diseases in dogs, potentially enabling a multi-disease testing panel. Future releases of the machine learning algorithm may require additional clinical evaluation and regulatory approval. The company believes its constantly learning A.I. software will become more accurate and expand into multiple abnormalities from a single sample over time. It plans to add additional advisors in the upcoming year and expects material changes in the number of employees over the next 12 months.

Management Comments

• "Our mission is to revolutionize early detection of a wide array of animal related abnormalities ranging from disease to potentially toxic environmental and food conditions."
• "Our initial priority will be to develop a breath test to detect early-stage and mature heartworm infections in dogs."
• "We believe breath analytics is an accessible, non-invasive, and convenient method for detecting disease."
• "We believe we will be able to isolate a breath print for heartworm that can be identified in all dogs for use in a test that outperforms traditional blood-based testing in a cost-effective manner."
• "We anticipate the completion (note that revisions will potentially be made based on data we obtain from use over time) of the components, the Heartworm Breath Test, and the verification and validation studies in 2026 that will be acceptable to begin commercialization."
• "We believe that the Heartworm Breath Test may be of substantial importance in preventing impairment of health through the diagnosis of a life-threatening disease for dogs."
• "Our projected timing to market with an upgrade and highly sensitive technology places us in a strong position relative to our competitors in the breath analytics space."
• "We believe the results of the Heartworm Breath Test will revolutionize heartworm detection."
• "We are confident that [Ellvin A.I. software] will be reliable for our purpose."
• "We believe we can be successful in all areas and consider obtaining Mindspace to be the most sensitive to our overall success."
• "The management of the Company believes that these material weaknesses [in internal controls] will remain until such time that the Company has the resources to increase the number of personnel committed to the performance of its financial duties."

Industry Context

Global Innovative Platforms operates in the animal health diagnostics market, specifically focusing on breath analysis, a novel technology. The current market for heartworm testing, estimated at 10 million dogs annually in the U.S. at $30-$50 per test, is dominated by antigen detection blood tests from companies like Idexx, Antech, and Zoetis. GIPL aims to disrupt this market by offering earlier, non-invasive, and potentially more cost-effective detection. The increasing prevalence of heartworm despite preventatives highlights a need for improved diagnostics. The company's partnership with Boehringer Ingelheim, a leading global animal health company, suggests a potential for significant industry validation and adoption, positioning GIPL as an innovator in the 'Animal Breathomics' space where it claims no other significant company is currently operating.

Comparison to Industry Standards

• Current leading heartworm tests (e.g., Idexx, Antech, Zoetis) typically require the heartworm to be approximately six months old for detection via antigen blood samples, whereas GIPL's breath test aims for earlier detection.
• GIPL's breath test is non-invasive, contrasting with traditional blood sample collection methods.
• The company believes its direct costs per use for the breath test will be less than a dollar, compared to approximately $5 plus discounts for current market leaders, suggesting a significant cost advantage.
• Current market tests do not perform with 100% sensitivity and 100% specificity, leaving room for improvement, which GIPL's 100% accuracy in research settings (albeit with a small sample size) aims to address.
• The delay of 6 months for reliable detection in current tests creates issues for veterinarians, pet owners, and pets, which GIPL's earlier detection capability seeks to resolve.

Corporate Governance

Legal Proceedings

• No material, existing or pending legal proceedings against the company or its officers, directors, or significant stockholders were reported.
• No proceedings in which any directors, officers, affiliates, or stockholders are adverse parties or have a material interest adverse to the company.

Related Party Transactions

• Andrew N. Brown, the sole officer and director, was awarded 2,135,000 shares for services in FY2025 and 1,650,000 shares in FY2024, valued at $3,630 and $2,805 respectively.
• The company's executive office space at 570 Lexington Green Ln, Sanford, FL, is furnished by its CEO, Andrew Brown, at a charge of $1,500 per month, with $1,500 accrued at September 30, 2025, and $16,500 paid in cash for the year.
• During FY2025, 1,750,000 shares of common stock were issued to related parties for services valued at $2,975.
• During FY2024, 490,000 shares were issued to related parties for services valued at $49, and 1,830,000 shares were issued to related parties for services valued at $183.
• As of October 1, 2023, three shareholders advanced $101,115 to the company, with an additional $25,000 advanced in FY2024.
• On September 27, 2024, $337,360 of debt, including related party advances, was converted into 5,267,268 shares of common stock.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity capital raises. The stock is thinly traded and subject to penny stock regulations, limiting liquidity and potentially causing price volatility. The going concern warning indicates a high risk of investment loss. However, the Boehringer Ingelheim partnership and promising early results offer potential for future value appreciation if commercialization is successful.
• **Employees (Andrew Brown):** Andrew Brown, the sole full-time executive, is heavily involved in all aspects of the business and receives stock awards for services. The company plans to add staff, which could benefit future employees.
• **Customers (Veterinarians, Pet Owners, Agricultural Industry):** Potential for earlier, non-invasive, and more cost-effective heartworm detection and multi-disease testing could significantly improve animal health outcomes and reduce costs. However, the technology is still in development and not yet commercialized, with no guarantee of market acceptance or accuracy on a large scale.
• **Suppliers (Defiant Technologies Inc.):** Benefits from license fees and future royalties on net sales of licensed products. The ongoing relationship is critical for GIPL's product development.
• **Creditors:** Face risk due to the company's recurring losses, accumulated deficit, and going concern status, making repayment uncertain without significant future financing or profitability.

Next Steps

• Gather additional samples from heartworm positive and negative dogs to finalize the algorithm for the Heartworm Breath Test.
• Progress to blinded confirmation of the algorithm test, utilizing approximately 100 breath samples to create initial efficacy statistics.
• Conduct additional tests to create market-desired statistics for the Heartworm Breath Test.
• Complete verification and validation studies for the components of the Heartworm Breath Test in 2026, aiming for commercialization.
• Continue development of non-invasive breath tests designed to detect up to nine diseases in dogs.
• Review and establish appropriate governance for cybersecurity oversight.
• Consider hiring or consulting with cybersecurity professionals and implementing employee training on cybersecurity awareness.
• Increase the number of personnel committed to financial duties to address material weaknesses in internal controls, including hiring additional personnel and retaining outside consultants.
• Add additional advisors to the Board in the upcoming year.
• Seek to raise additional debt and/or equity financing to meet ongoing operating expenses and develop operations.

Key Dates

Recommendation

Despite promising early research results and a recent partnership with Boehringer Ingelheim, Global Innovative Platforms Inc. presents an extremely high-risk investment. The company has generated no revenue for the past two fiscal years, reported a substantial net loss of $718,251 in FY2025, and carries an accumulated deficit of over $1.2 million. The independent auditor has issued a 'going concern' warning, indicating significant doubt about the company's ability to continue operations without substantial additional financing, which is not guaranteed. Furthermore, the company has identified material weaknesses in its internal controls over financial reporting, lacks independent board oversight, and its stock is thinly traded and subject to penny stock regulations, all of which increase operational and investment risk. While the technology has potential, the current financial instability, governance issues, and early stage of commercialization make it a 'strong sell' for any seasoned investor or institution, as the risk of capital loss far outweighs the speculative upside.

Keywords

Animal Health, Breath Analysis, Heartworm Detection, Veterinary Diagnostics, VOCAM Plus, FROG Device, Artificial Intelligence, Non-invasive Testing, SEC Filing, 10-K, Biomarkers, Gas Chromatography, Defiant Technologies, Boehringer Ingelheim